CA2120927A1 - Enhanced skin penetration system for improved topical delivery of drugs - Google Patents
Enhanced skin penetration system for improved topical delivery of drugsInfo
- Publication number
- CA2120927A1 CA2120927A1 CA002120927A CA2120927A CA2120927A1 CA 2120927 A1 CA2120927 A1 CA 2120927A1 CA 002120927 A CA002120927 A CA 002120927A CA 2120927 A CA2120927 A CA 2120927A CA 2120927 A1 CA2120927 A1 CA 2120927A1
- Authority
- CA
- Canada
- Prior art keywords
- drugs
- hydrochloride
- drug
- group
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8158—Homopolymers or copolymers of amides or imides, e.g. (meth) acrylamide; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
Abstract
The invention involves pharmaceutical compositions for topical application comprising: (a) a safe and effective amount of a pharmaceutical active; and (b) from about 0.05 % to about 5 % of a non-ionic polyacrylamide having a molecular weight of from about 1,000,000 to about 30,000,000.
Description
.' '`.
W O 93/07902 2 i 2 Q ~ 2 7 P~/US92/08741 ENHANCED SKIN PENETRATION SYSTEM FOR
IMPROVED TOPICAL DELIVERY OF DRUGS
TCHNICAL fIELD
The present invention relates to compositions for the topical administration of drugs, especially such compositions having enhanced penetration of the drug through the skin.
~ACKGROUND O~_THE INVENTION
Because of the accessibility and large area of the skin, it has long been considered a promising route for the administration of drugs, whether derma1, re~ional, or systemic effects are desiret.
The advantages of the topical route of drug administration include: avoidance of the risks and inconvenience of parenteral treatment; avoidance of the variable absorption and metabolism associated with oral treatment; continuity of drug administration, permitting use of pharmacologically active agents with short biological half-lives; potential reduction of gastrointestinal irritation in systemic administration; and treatment of curtaneous manifestations of diseases usually treated systemically.
~owever, the imper~eability of skin is well-known, serving as a barrier to ingress of pathogens and toxic chemicals, and egress of physiologic fluids. This impermea~ility is the result of nonmal physiologic changes in developing skin. A typical cell in the epidermis is forme~ in the basal layer. It typically takes approximately thirty days for a cell to migrate from the basal layer of the epidermis to sloughing off and discarding at the outer layers of the stratum corneum. As the cell migrates outward from the basal layer, it progressively keratinizes until it is relatively impermeable. The result is the stratum corneum, an extremely thin surface layer (10 microns) with substantial barrier properties. The cell envelopes of the cells in the stratum .
W O 93/07902 2 i 2 Q ~ 2 7 P~/US92/08741 ENHANCED SKIN PENETRATION SYSTEM FOR
IMPROVED TOPICAL DELIVERY OF DRUGS
TCHNICAL fIELD
The present invention relates to compositions for the topical administration of drugs, especially such compositions having enhanced penetration of the drug through the skin.
~ACKGROUND O~_THE INVENTION
Because of the accessibility and large area of the skin, it has long been considered a promising route for the administration of drugs, whether derma1, re~ional, or systemic effects are desiret.
The advantages of the topical route of drug administration include: avoidance of the risks and inconvenience of parenteral treatment; avoidance of the variable absorption and metabolism associated with oral treatment; continuity of drug administration, permitting use of pharmacologically active agents with short biological half-lives; potential reduction of gastrointestinal irritation in systemic administration; and treatment of curtaneous manifestations of diseases usually treated systemically.
~owever, the imper~eability of skin is well-known, serving as a barrier to ingress of pathogens and toxic chemicals, and egress of physiologic fluids. This impermea~ility is the result of nonmal physiologic changes in developing skin. A typical cell in the epidermis is forme~ in the basal layer. It typically takes approximately thirty days for a cell to migrate from the basal layer of the epidermis to sloughing off and discarding at the outer layers of the stratum corneum. As the cell migrates outward from the basal layer, it progressively keratinizes until it is relatively impermeable. The result is the stratum corneum, an extremely thin surface layer (10 microns) with substantial barrier properties. The cell envelopes of the cells in the stratum .
2 1 2 0 !3 2 7 PCI`/US92/08741 corneum tend to be mainly polar lipids, such as ceramides, sterols, and fatty acids while the cytoplasm of stratum corneum cells remains polar and aqueous. Despite the close packing of the cells, some 15% of the stratum corneum is intercellular and, generally, lipid based. It is generally recognized that over the very short term, penetration occurs through the hair follicles and the sebaceous apparatus; long-term penetration occurs across cells (non-polar route). Poor penetration of many drugs across the epidermal lipid barrier has, until now, frustr-ted attempts to deliver clinically significant doses of ~any drugs by the topical route.
One route of internal delivery of drugs is by transdermal administration. Transdermal administration of drugs can be used in many instances to achieve therapeutic levels of the drugs in the systemic circulatory system, as well as for more localized internal dosing of drugs. ~here such therapeutic levels of drugs can be achieved by transdermal administration, several potenti~l advantages exist over other routes of administration. Sustained systemic delivery of drug controlled at therapeutic but below toxic levels over long periods of time with a single continuous application is often an advantage of transdermal drug administra-tion. Potential contamination of int~rnal tissues with undesired foreign substances or microbes, often associated with parenteral administration of drugs, is avoided with transdermal drug admin-istration. Or~l administration of many drugs is undesirable or unfeasible because the drug decomposes in the harsh environment of the gastrointestinal tract, lacks sufficient absorption from the gastrointestinal tract, or causes gastrointestinal upset or tissue damage in the gastrointestinal tract. First-pass metabolism of orally administered drugs can increase the dosage required to achieve therapeutic levels and thereby increase undesirable side effects either from the primary drug or the metabolites. Main-tenance of uniform, optimal systemic levels of drugs for long periods of time is often difficult through oral administration.
Such problems can often be reduced or avoided by transdermal drug administration.
W O 93/07902 2 1 2 0 ~ 2 7 P~/US92/08741 Despite the substant~al potential advantages for transdermal administration of drugs, relatively few drugs are so administered.
The skin is a formidable barrier to the passage of mast drùgs. It is often necessary to provide a composition containing a skin penetra~ion enhancing vehicle in order to provide sufficient transdermal penetration of the dru9 to achieve therapeutic levels of the drug at the target internal tissue. A number of skin penetration enhancing vehicles for drugs have be~n disclosed, including those in the following references: U.S. Patent No.
One route of internal delivery of drugs is by transdermal administration. Transdermal administration of drugs can be used in many instances to achieve therapeutic levels of the drugs in the systemic circulatory system, as well as for more localized internal dosing of drugs. ~here such therapeutic levels of drugs can be achieved by transdermal administration, several potenti~l advantages exist over other routes of administration. Sustained systemic delivery of drug controlled at therapeutic but below toxic levels over long periods of time with a single continuous application is often an advantage of transdermal drug administra-tion. Potential contamination of int~rnal tissues with undesired foreign substances or microbes, often associated with parenteral administration of drugs, is avoided with transdermal drug admin-istration. Or~l administration of many drugs is undesirable or unfeasible because the drug decomposes in the harsh environment of the gastrointestinal tract, lacks sufficient absorption from the gastrointestinal tract, or causes gastrointestinal upset or tissue damage in the gastrointestinal tract. First-pass metabolism of orally administered drugs can increase the dosage required to achieve therapeutic levels and thereby increase undesirable side effects either from the primary drug or the metabolites. Main-tenance of uniform, optimal systemic levels of drugs for long periods of time is often difficult through oral administration.
Such problems can often be reduced or avoided by transdermal drug administration.
W O 93/07902 2 1 2 0 ~ 2 7 P~/US92/08741 Despite the substant~al potential advantages for transdermal administration of drugs, relatively few drugs are so administered.
The skin is a formidable barrier to the passage of mast drùgs. It is often necessary to provide a composition containing a skin penetra~ion enhancing vehicle in order to provide sufficient transdermal penetration of the dru9 to achieve therapeutic levels of the drug at the target internal tissue. A number of skin penetration enhancing vehicles for drugs have be~n disclosed, including those in the following references: U.S. Patent No.
3,536,816 issued to Kellner on October 27, 1970; U.S. Patent No.
4,006,218 issued to Sipos on February 1, 1977; U.S. Patent No.
4,124,720 issued to Wenmaekers on November 7, 1978; U.S. Patent No. 4,126,681 issued to Reller on November 21, 1978; U.S. Patent No. 4,299,826 issued to Luedders on Hovember 10, 1981; U.S. Patent No. 4,305,936 issued to Klein on December 15, 1981; U.S. Patent No. 4,309,~14 issued to Inagi, Muramatsu ~ Nagai on January 5~
1982; U.S. Patent No. 4,338,306 issued to Kitao ~ Nishimura on July 6, 1982; U.S. Patent No. 4,442,090 issued to Kakeya, Kitao Nishimura on April 10, 1984; U.S. Patent No.~ 4,485,033 issued to Kitao ~ Nishimura on November 27, 1984; U.S. Patent No. 4,537,776 issued to Cooper on August 27, 1985; U.S. Patent No. 4,5S2,872 issued to Cooper, Loomans ~ Fawzi on November 12, 1985; U.S.
Patent No. 4,557,934 iss~ed to Cooper on December 10, 1985; U.S.
Patent No. 4,S73,995 is~ed to Chen, Chun ~ Enscore on March 4, 1986; U.S. Patent No. 4,626,539 issued to Aungst & DiLuocio on ~ecmber 2, 1986; U.S. Patent No. 4,637,930 issued to Konno, Kawata, Aruga, Sonobe & Mitomi issued January 20, 1987; U.S.
Patent No. 4,695,465 issued to Kigasawa, Ohtani, Tanaka Hayashida on September 22, 1987; European Patent Application No.
0,043,738 of The Procter ~ Gamble Company in the names of ~ickett, Cooper ~ Loomans, publtshed on June 13 1982; European Patent Applica~ion No. 0,095,813 of The Procter ~ Gamble Company in the name of Cooper, published Deeember 7, 1983; PCT International Patent Application No. WO 87/03490 of Key Pharmaceuticals, Inc. in the names of Bodor and Loftson, published on June 18, 1987;
Washitake, M., T. Anmo, 1. laaaka, T. Arita L H. Nakano, WO g3/07902 PCI/US92/08741 ~Pereutaneous Absorption of Drugs from Oily Yehicles~, Journal of Pharmaceutical Sciences, Vol. 64, No. 3 (March, 1975), pp.
397-401; Shahi, V., ~ J. L. Zatz, ~Effect of Formulation Factors on Penetration of Hydrocortisone through Mouse Skin~, Journal of Pharmaceutical Sciences, Vol. 67, No. 6 (June, 19~8), pp. ~89-792;
Cooper, E.R., ~Increased Skin Permeability for Lipophilic Mole-cules~, Journal of Pharmaceutical Sciences, Vol. 73, No. 8 (August, 1984), pp. 1153-1156; Aungst, 8.J., N. J. Rogers ~ E.
Shefter, ~Enhancement of Naloxone Penetration through Human Skin 1Q Vitro Using Fatty Acids, Fatty Alcohols, Surfactants, Sul-~oxides and Amides~, In~D~ion~l Journal of Pharmaceutics, Vol.
33 (1986), pp. 225-23~; Green, P.6., ~ J. Hadgraft, ~Facilitated Transfer of Cat10nic Drugs Across a Lipoidal Membrane by Oleic Ac~d and Lauric Acid~, Internation~l Journal of Pharmaceutics, Vol~ 37 (J~ly, 1987), pp. 251-255.
It is an object of the present invention to provide novel compositions for enhancing the skin penetratton of drugs.
It i s a further object of the present invention to provide such compositions which provide sufficient skin penetration enhancement to achieve therapeutic levels of the drugs in target internal tissues.
It is a further object of the present invention to provide such compositions with low dermal irritation, especially in compositions requiring a low pH.
It is a still further object of the present invention to provide such compositions having good stability and good cosmetics.
SUMMARY OF THE INVENTIQN
The present invention relates to pharmaceutical compositions for topical application having enhanced penetration through the skin comprising:
(a) a safe and effective amount of a pharmaceutical active;
and (b) from about 0.05% to about 20% of a non-ionic 3s ` polyacrylamide having a molecular wight of from about 1,000,000 to about 30,000,000.
W O 93/07902 ~12 ~ ~ ~ 7 P~/US92/08741 All concentrations and ratios herein ~re b~ ~ei~ht of tot~l co~positton and all measurements are at 25C, unless otherwise spec~fied.
~ETAILED DESCRIPTION QE THE INVENTION
The present invention involves compos~ttons compr1s~ng certain specif~c non-ionic polymers which may be ~pplied topic~lly to the skin and which result in improved transdermal penetration of the drugs through the skin. These compositions also have a high solvent tolerance, i.e.~ high level of solvents such as alcohol and other water-soluble componants which may be necessary to solubilize the active can be included in the compositions.
~rua Act~ve The compositions of the present invention comprise a safe and effective amount of a drug active. The phrase ~safe and effectiv~
amount~, as used herein, means an amount of a drug high enough to significantly positively modify the condition to be tre~ted, but low enough to avoid serious side effects (at a reasonable benefit/risk r~tio), within the scope of sound medical judgement.
A safe and ~ffective amount of the drug ~will vary with the spectfic drug, the ability of the composition to penetrate the drug through the skin, the ~mount of composition to be applied, the p~rticular condition being treated, the age and physical cond~tion of ~he patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent ther~py, and ljke factors.
~he drug compounds present in the compositions of the present invention preferably comprise from about O.lX to about 20%
by weight of the compositions, more preferably from aboutO.1% to about lOX~ and most preferably from about 0.1% to about 5%.
Mixtures of drug actives may also be used.
Useful drug actives in the compositions of the present invention include anti-acne drugs. Anti-acne drugs preferred for use in the present invention include the keratolytics such as salicylcic acid, sulfur, lactic acid, glycolic, pyruvic acid, 3; urea, resorcinol, and N-acetylcysteine; retinoids such as retinoic acid and its derivatives (e.g., cis and trans);
WO 93/07902 2 1 2 0 9 2 7 PCI`/US92/OX741 antibiotics and antimicrobials such as benzoyl peroxide, octopirox, erythromycin, tetracyclin, triclosan, azel aic acid and its derivatives, phenoxy ethanol and phenoxy proponol, ethylacetate, clindamycin and meclocycline; seb~stats such as flavinoids; hydroxy acids; and bile salts such as scymnol sulfate and its derivatives, deoxycholate, and cholate.
Useful drug actives in the compositions of the present invention include non-steroidal anti-inflammatory drugs (NSAIDS).
The NSAIDS can be selected from the following categories:
propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams.
All of these NSAIDS are fully described in the U.S. Patent 4,985,459 to Sunshine et al., issued January 15, 1991, incorporated by reference herein. Most preferred are the propionic NSAIDS including but not limited to aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, ~ uprofen and bucloxic acid. Also useful are the steroidal anti-inflammatory drugs including hydrocortisone and the like.
Useful drug actives in the compositions of the present invention include antihistaminic drugs. Antihistaminic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chlorpheniramine, triprolid~ne, diphenhydramine, doxylamine, pyrilamine, phenindamine, promethazine, cyproheptadine, azatadine, clemastine, carbinoxamine, tripelennamine, terfenadine, dexchlorpheniramine, brompheniramine, chlorcyclizine, diphenylpyraline, pheniramine and phenyltoloxamine, and mixtures thereof.
Useful drug actives in the compositions of the present invention include antitussive drugs. Antitussive drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of dextromethorphan, codeine, caramiphen and carbetapentane.
? WO 93/07902 . 212 0 9 2 7 PCI~/US92/08741 Useful dr~g actives in the compositions of the present invention include antipruritic drugs. Antipruritic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of methdilizine and trimeprazine.
Useful drug actives in the compositions of the present invention include anticholinergic drugs. Anticholinergic drugs preferred for inclusion in compositions of the present invention include phar~aceutically-acceptable salts of scopolamine, atropine, homatropine, levodopa, dicyclomine, hyoscyamine, procyclidine, trihexyphenidyl and ethopropaz~ne.
Useful drug actives in the compositions of the present invention include anti^emetic and antinauseant drugs. Anti-emetic and antinauseant drugs proferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of cyclizine, meclizine, chlorproma2ine, bucli2ine, metoclopramide, prochlorperazine and trimethobenza~ide.
Useful drug actives in the compositions of the present invention include anorexic drugs. Anorexic~drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of benzphetamine, phentermine, chlorphentermine, fenfluramine, diethylpropion and phendimetrazine.
Useful drug acttves in the compositions of the present invention include central stimulant drugs. Central stimulant drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of amphetamine, methamphetamine, dextroamphetamine and methylphenidate.
Useful drug actives in the compositions of the present invention include antiarrhythmic drugs. Antiarrhythmic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of propranolol, procainamide, disopyramide, quinidine, encainide, flecanaide, mexiletine and tocainide. Other antiarrhythmic drugs preferred for inclusion in compositions of the present invention include W O 93~07902 2~ 20 9~7 PCI/US92/08741 pharmaceutically-acceptable salts of th~ quinidine derivatives disclosed in U.S. Patent No. 4,716,171 issued to Jarreau and Koenig on December 29, 1987, which is hereby incorporated herein in its entirety by reference. Highly preferred compounds included in this class include pharmaceutically-acceptable salts of 3S-hydroxy-10,11-dihydroquinidine, 3R-hydroxy-10,11-dihydro-quinidine, 3R-hydroxy-O-acetyl-10,11-dihydroquinidine, and 3S-hydroxy-O-acetyl-10,11 -dihydroquinidine, especially 3S-hydroxy-10,11-dihydroquinidine.
Use~ul drug actives in the compositions of the present invention include ~-adrenergic blocker drugs. ~-Adrenergic blocker drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of metoprolol, acebutolol, betaxolol, labetalol and timolol.
~-Adrenergic blocker drugs more preferred for inclusion in compositions of the present invention include metoprolol tartrate, acebutolol hydrochloride, betaxolol hydrochloride, labetalol hydrochloride and timolol maleate.
Useful drug actives in the composit~ons of the present invention include cardiotonic drugs. Cardiotonic drugs preferred for inclusion in compositions of the present invention i,nclude pharmaceutically-acceptable salts of milrinone, amrinone and dobutamine. Other cardiotonic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of 14-amino steroid derivatives, some of which are disclosed in U.S. Patent Nos. 4,325,879, ~,552,868 and 4,584,289, issued to Jarreau and Koenig on April 20, 1982, November 12, 1985 and April 22, 1986, respectively, each of which are hereby incorporated herein in their entirety by reference.
Useful drug actives in the compositions of the present invention include antihypertensive drugs. Antihypertensive drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of enalapril, clonidine, ~5 hydralazine, minoxidil (whieh is also a hair growth stimulator ` ~ W O 93/07902 2 1 2 0 ~ 2 7 PCT/US92/08741 drugJ, guanadrel, guanethid1ne, guanfacine, mecamylamine, methyldopate, pargyline, phenoxybenzamine and prazosin.
Useful drug actives in the compositions of the present inventi~n include diuret k drugs. Diuretic drugs preferred for inclusion in compositions of the present invention include pharma-ceutically-acceptable salts of amiloride and hydrochlorothiazide.
Diuretic drugs more preferred for inclusion in compositions of the present invention include amiloride hydrochloride.
Usefut drug actives in the compositions of the present invent10n include vasod~lator drugs. Vasodilator drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of diltazem, amiodarone, isoxsuprine, nylidrin, tolazoline and verapamil.
Useful drug actives in the compositions of the present invention include vasoconstrictor drugs. Vasoconstrictor drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of dihydroergotamine, ergotamine and methysergide.
Useful drug actives in the compositions of the present invention includes anti-ulcer drugs. Anti-ulcer drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of ranitidine and cimetidine.
Useful drug actives in the composit~ons of the present invention inolude include anesthetic drugs. Anesthetic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of lidocsine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine and phenol.
Useful drug actives in the compositions of the present invention include ant~depressant drugs. Antidepressant drugs preferred fur inclusion in compositions of the present invention include pharmaceutically-acceptable salts of imipramine, desipramine, amitriptyline, nortriptyline, protriptyline, doxepin, maprotiline, phenelzine, tranylcypromine, trazodone and trimipramine.
WO 93~07902 2 ~-~ 9 ~ ~7 PCI /US92/08741 - 1 0 - .
Useful drug actives in the compositions of the present invention include tranquilizer and sedative drugs. Tranquilizer and sedative drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chlordiazepoxide, benactyzine, benzquinamide, flurazepam, hydroxyzine, loxapine and promazine.
Useful drug actives in the compositions of the present invention include antipsychotic drugs. Antipsychotic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chlorprothixene, fluphenazine, haloperidol, molindone, thioridazine and trifluoperazine.
Useful drug actives in the compositions of the present invention include antimicrobial drugs (antibaeterial, antifungal, antiprotozoal and antiviral drugs). Antimicrobial drugs preferred for inclusion in compositions of the present invention include phanmaceutically-acceptable salts of ~-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracyoline, clindamycin, ethambutol, metronidazole~ pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minooycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, micona~ole and amanfadine.
Antimicrobial drugs preferred for inclusion in compositions of the present invention include tetracycline hydrochloride, erythromycin estolate, erythromycin stearate (salt), amikacin sulfate, doxycyetine hydrochloride, capreomycin sulfate, chlorhexidine gluconate, ehlorhexidine hydrochloride, chlortetracycline hydro-chloride, oxytetracycline hydrochlaride, clindamycin hydro-chloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride? methacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmicin sulfate, paromomycin sulfate.
streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate~
`WO 93/07902 21 2 0 !3 2 7 PCl/US92/08741 triclosan, octopirox, parachlorometa xylenol, nystatin, tolnaftate and clotrimazole.
Useful drug actives in the compositions of the present invention include antineoplastic drugs. Antineoplastic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of bleomycin, daunorubicin, doxorubicin, mechlorethamine, procarbazine, quinacrine, tamoxifen, vinblastine and vincristine.
Useful drug actives in the compositions of the present invention include antimalarial drugs. Antimalarial drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chloroquine, hydroxychloroquine primaquine and quinine.
Useful drug actives in the compositions of the present invention include muscle relaxant drugs. Muscle relaxant drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of cinnamedrine, cyclobenzaprine, flavoxate, orphenadrine, papaverine, mebeverine, idaverine, ritodrine, dephenoxylate, dantrolene and azumolene.
Useful drug actives in the compositions of the present invention include antispasmodic drugs. Antispasmodic .drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of the compounds disclosed in U~S. Patent Number 3,856,825 issued to ~right, Burch and Goldenburg on December 24, 1974, which is hereby incorporated herein in its entirety by reference.
Useful drug actives in the compositions of the present invention include antidiarrheal drugs. Antidiarrheal drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of loperamide.
Useful drug actives in the compositions of the present invention include bone-active drugs. Bone-active drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of diphosphonate drug compounds and phosphonoalkylphosphinate drug compounds, including the prodrug esters thereof. Such compounds are disclosed~ for 21209~
WO 93/0~902 - 1 2 - PCI~/US92J08741 exa~ple, in U.S. Patent Nos. 3,683,080 issued to francis on August 8, 1972; 4,304~734 issued to Jary, Rihakova ~ Zobacova on December 8, 1981; 4,687,768 issued to 8enedict ~ Johnson on August 18, 1987; 4,711,880 issU2d to Stahl ~ Schmitz on December 8, 1987; and 4,719,203 issued to Bosies h ~all on January 12, 1988; copending U.S. patent application Serial Nos. 808,584, of Benedict ~ Perkins filed December 13, 1985; 945,069 of Ebetino, Buckingham ~ McOsker filed Dece~ber 19, 1986; 945,068 of Ebetino ~ Benedict filed Dece~ber 19, lq86; and 069,666 of Ebetino filed July 6, 1987; and Europe~n Patent Application Hos. 0,001,584 o~ Blum, Hempel ~or~s, published May 2, 1979; 0,039,033 published April 11, 1981;
0,186,405 of Benedict ~ Perk~ns, published July 2, 1986; and 0,2~3,173 of Oku, Todo, Kasah-ra, Nakamura, Kayakiri ~ Hashimoto, published October 28, 1987; all of which are hereby incorporated herein in their entirety by reference.
Also useful in the present invention 2re sunless tanning agents including dihydroxyacetone, indole derivatives, and the like. These sunless tanning ag~nts ~ay also be used in co~binat~on with conventional sunscreen agents such as those disclosed in Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Tç~hnoloqY, incorporated by reference herein, as well as wound healing agents such as peptide derivatives, yeast, panthennl, Iamin and kinetin.
Other usefulskin actives include skin bleaching (or 1 ightening) agents incluJing but not 1 imited to hydroquinone, ascorbic acid, kojic acid and sodium metabisul~ite.
NQnionic Polvacrylamide The non-ionic polymers useful in the present invention are polyacrylamides and substituted polyacrylamides, branched or unbranched. These polymers are non-ionic water-dispersable polymers which can be formed from a variety of monomers inoluding acrylamide and methacrylamide which are unsubstituted or substituted with one or two alkyl groups (preferably Cl-Cs). Preferred acrylate amides and methacrylate amides in which the amide nitrogen is unsubstituted, or 3~ substituted with one or two Cl-Cs alkyl groups (preferably:
methyl, ethyl or propyl), for example, acrylamide, methacrylamide, (*See page 19 for equivalent~.) .- .. .
W O 93/07902 212 0 ~ 2 7 P~/US92~08741 N-methylacrylamide, N-methylmethacrylamide, N,N-dimethylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide and N,N-dimethylacrylamide. These monomers are senerally disclosed in U. S. Patent 4,963,348 to Bolich, Jr. et al., issued October 16, 1990, incorporated by reference herein in its entirety. These copolymers may optionally be for~ed using conventional neutral crosslinking agents such as dialkenyl co~4ounds. The use of such crossltnking agents for cat10nic polymers is disclosed in U.S. Patent ~,628,078 to Glover et al. issued December 9, 1986 and U.S. P~tent 4,599,379 to Flesh~r et al. issued July 8, 1986 both of ~h~ch are incorporated by reference herein. These non-ionic co-poly~ers have a molecular weight greater than about 1,000,000 preferably greater than about 1,500,000 and range up to about 30,000,000. Preferably, as a result of being synthesized by reverse phase emulsion polymerization, these non-ionic polyacrylamides are predispersed in a water-im~isc~ble solvent such as mlneral oil and the like~
containing a high HLB surfactant (HLB from about 7 to about 10) which helps to facilitate water dispersibility of the polyacrylamide. Most preferred for use herein is the non-ionic polymer under the ~TFA designation: polyacrylamide and isoparrafin and laureth-71 available as Sepigel from Seppic Corporation.
These non-ionic polyacrylamides are present at a level from about 0.05% to about 20%, preferably from about 0.05% to 5% and most preferably from about 0.1% to about lOX.
Vehiçle The compositions of the present invention are used atong with pharmaceutically-acceptable carrier (or vehicle) components. The term "pharmaceutically-acceptable carrier components~, as used herein, means compatlble solid or liquid filler diluents which are suitable for administration to a human or lower animal. The term ~compatible~, as used herein, means that the components are capable of being commingled with the drug compounds, diols and fatty acids of the compositions of the present invention, and with each other, in a manner such that 3~ there is no interaction which would substantially reduce the pharmaceutical efficacy of the compositions of the present WO 93/07902 P~/US92~08741 2120!~7 invention under ordinary use situations.
Pharmaceutically-acceptable carrier components must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitab1e for administration to the human or lower animal being treated.
Some examples of substances which can serve as pharmaceuti-cally-acceptable carrier components are polyethylene glycol;
glycerol; ethanol; water; antioxidants; surfactants; chelating agents; preservatives; thickeners; as well as other non-toxis com-patible substances used in pharmaceutical formulat~ons.
These compositions can also contain one or more humectants/moisturizers many of which may also be useful as pharmaceutical actives. A variety of humectants/moisturizers can be employed and can be present at a level of from about 1% to about 30%, more preferably from about 2% to about 8% and most preferably from about 3X to about 5%. These materials include polyhydroxy alcohols such as sorbitol, glycerin, hexanetriol, propylene glycol, hexylene glycol and the like; polyethylene glycol; sugars and starches; sugar and starch deriYatives (e.g.
alkoxylated glucose)~ D-panthenol; hyaluronic acid; lactamide monoethanolamine; acetamide monoethanolamine; and mixtures thereof.
Preferr~d humectants/moisturizers for use in the compositions of the present in~ention are the C3-C6 diols and triols.
Especially preferred is the triol, glycerin. The compositions of this invention may also contain pharmaceutically acceptable optional components that modify the physical and/or therapeutic effects of the compositions~ Such optional components may include, for example, additional solvents, emulsifiers, gelling agents, fragrances, preservatives, and stabilizers. However, such optional materials must not unduly interfere with the transdermal delivery of the drug active. Optional components useful in the compositions of this invention are described in the following patent documents, incorporated by reference herein: European Patent Publieation 43,738, Wickett et al., published January 13, WO 93/07902 212 0 ~ 2 7 PCI~/US92/08741 1982; and U.S. Patent 4,552,872, Cooper et al., issued November 12, 1985.
Most preferred compositions herein are gel-type compositions.
Another optional material is a solvent or co-solvent material. Such solYent materials include, for example, short chain alcohols and ethers. Preferred optional solvent materials include polyethylene glycols, dipropylene glycol, ethylene glycol monoethyl ether, ethanol, isopropanol, and dimethyl isosorbide.
~ater may also be used as a solvent or co-solvent in the compositions of this inven~ion. I~ water is used in a saturated system, a gel or emulsion is preferably formed.
Most preferred compositions have a pH of below about 5, preferably below about 4, and most preferably below about 3.
While particular embodiments of the present invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the compositions d1s-closed herein can be made without departing from the spirit and the scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.
Test Method Transdermal penetration of drugs is convenieotly determined and compared from various vehicles using the apparatus and procedure described below.
Full thickness excised human thigh skin is obtained from cadavers after all hair had been clipped and the skin washed. The skin samples are then bathed in 10% glycerin and stored frozen.
The glycerin prevents the formation of ice crystals which could possibly damage the keratinized cells and/or the intercellular lipid matrix. After a rapid thawing, the skin is conditioned for 24 hours in Hank's Balanced Salt Solution with 1%
antibacterial-antimycotic solution. Then the skin is washed with distilled water. A single skin donor is used for each experiment, and individual sections for use are selected based on integrity of the stratum corneum (visual determination). Selected areas are cut to 1cm2 using a scalpel.
WOg3~07gO2 -16- PCI~/USg2/08741 Tests are conducted using glass diffusion cells placed 1n temperature-regulated stirring modules- Skin sections are mounted in the cells, and the receptor phase is added. The receptor phase is SOX Hank's Balance Salt Solution with 1% antibiotic-antimycot;c solution. Each diffusion cell has an exposed are~ of 0.79cm2 and a receptor capacity of Sml. Sufficient formulation is applied (750ul) to the surface of the skin to ensure infinite dose conditions, and the diffusion cell is covered with plastic wrap or parafilm to prevent product evaporation. At each sampling time the receptor phase is removed for analysis of drug content. The receptor phase is removed for analysis of drug content. The receptor phase is replenished at each sampling time in order to maintain sink conditions. Preferably 3 to 6 replicates are run with sa~pling intervals occurring at l, 2, 4 ~ 6 hours.
Penetration rate (Flux) is deter~ined as the quantity of drug penetrating a measured area of skin per hour during the S hour interval between l hour and 6 hours. Generally steady state is reached before 1 hour. Penetration rate is usually expressed as ug drug per cm2 skin per hour.
The following examples further describe and demonstrate embodiments within the scope of the present invention.. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
Ingredients are identified by chemical or CTFA name.
WO 93~07902 PCI/US92~08741 212 0 !~ 2 7 "
E~AMPLES
ExamPle I
An anti-acne composition is made by combining the following ingredients.
In~ edient (YOW~W?
~ater, Purified 52.395 Alcohol SDA 40 40.000 Polyacrylamide and C13 14 Isoparaffin and Laureth-7 4.000 Salicylic Acid 2.000 Glycerin 1.000 Aloe Vera Gel 0.500 Menthol 0.100 Disod~um EDTA 0.005 ~he alcohol is added to a suitable si~e container. Using a Lightnint ~ixer with a 3 blade paddle prop, the salicylic acid is added to the alcohol and mixed at low speed (100 rpm) until the salicylic acid is dissolved. Menthol is added to the alcohol and mixed until dissolved. Separately, water is added to a su~table size container. Aloe vera gel and disodium EDTA are added to the water and mixed at low speed (100 rpm) until completely dissolved.
The water phase is then added to the alcohol phase and mixed until clear. Gylcerin is added and mixed until clear. While mixing at moderate speed (300 rpm~, the polyacrylamide and C13 14 isopara~fin and laureth-7 is added to form a gel. The resulting gel is mixed at moderate speed until uniform.
An anti-acne and/or analgesic composition is made by combining the following ingredients utilizing conventional mixing techniques as described above in Example I.
3~
Inaredient ~%W/~
Water, Purified 55.0 Ibuprofen 2.0 Alcohol SDA 40 40.0 Polyacrylamide and C13 l4 Isoparaffin and Laureth-7 ~.0 The compositions display skin penetration of the Ibuprofen active as well as improved skin feel and residue characteristics together with excellent moisturizing, e~olliency, rub-in and absorption characterist~cs.
ExamDle III
A keratotytic composition for dermatological disorders is made by combining the following ingredients utilizing conventional mixing techniques as described above in Example I.
: Inaredient (%~
Water 86.5 - Urea 10.0 Benzyl Alcohol 0.5 Polyacrylamide and C13 14 Isoparaffin and Laureth-7 3~0 The compositions display skin penetration of the Urea active as well as improved skin feel and residue characteristics together with excellent moisturizing, emolliency, rub-in and absorption characteristics.
ExamDle IV
A composition for sunless tanning is made by combining the following ingredients utilizing conventional mixing techniques as described above in Example 1.
' ~ 35 ~, :~
.
` W O 93/07902 2 1 2 g 9 2 7 P ~ /US92/08741 ,Inqredient (YOW/W) Water 91.5 Benzyl Alcohol 0.5 Polyacrylamide and C13 14 Isoparaffin and Laureth-7 3.0 Dihydroxyacetyone 3.Q
Glycerin 2.0 Th~ compositions display improved skin penetration of the dihydroxyacetone as well as improved skin feel and residue charac-teristics together with excellent moisturizing, emolliency, rub in and absorption character~stics.
(*~quivalents: USSN 808584 equivale~t to US Patent 4,90~,679;
USSN 945069 equivalent to US Patent 4,868,164; USS~ 945068 equivalent to EP Patent 0,274,158; and ~SS~ 069666 equivalen$ to EP ~ppln. 298,553.)
4,124,720 issued to Wenmaekers on November 7, 1978; U.S. Patent No. 4,126,681 issued to Reller on November 21, 1978; U.S. Patent No. 4,299,826 issued to Luedders on Hovember 10, 1981; U.S. Patent No. 4,305,936 issued to Klein on December 15, 1981; U.S. Patent No. 4,309,~14 issued to Inagi, Muramatsu ~ Nagai on January 5~
1982; U.S. Patent No. 4,338,306 issued to Kitao ~ Nishimura on July 6, 1982; U.S. Patent No. 4,442,090 issued to Kakeya, Kitao Nishimura on April 10, 1984; U.S. Patent No.~ 4,485,033 issued to Kitao ~ Nishimura on November 27, 1984; U.S. Patent No. 4,537,776 issued to Cooper on August 27, 1985; U.S. Patent No. 4,5S2,872 issued to Cooper, Loomans ~ Fawzi on November 12, 1985; U.S.
Patent No. 4,557,934 iss~ed to Cooper on December 10, 1985; U.S.
Patent No. 4,S73,995 is~ed to Chen, Chun ~ Enscore on March 4, 1986; U.S. Patent No. 4,626,539 issued to Aungst & DiLuocio on ~ecmber 2, 1986; U.S. Patent No. 4,637,930 issued to Konno, Kawata, Aruga, Sonobe & Mitomi issued January 20, 1987; U.S.
Patent No. 4,695,465 issued to Kigasawa, Ohtani, Tanaka Hayashida on September 22, 1987; European Patent Application No.
0,043,738 of The Procter ~ Gamble Company in the names of ~ickett, Cooper ~ Loomans, publtshed on June 13 1982; European Patent Applica~ion No. 0,095,813 of The Procter ~ Gamble Company in the name of Cooper, published Deeember 7, 1983; PCT International Patent Application No. WO 87/03490 of Key Pharmaceuticals, Inc. in the names of Bodor and Loftson, published on June 18, 1987;
Washitake, M., T. Anmo, 1. laaaka, T. Arita L H. Nakano, WO g3/07902 PCI/US92/08741 ~Pereutaneous Absorption of Drugs from Oily Yehicles~, Journal of Pharmaceutical Sciences, Vol. 64, No. 3 (March, 1975), pp.
397-401; Shahi, V., ~ J. L. Zatz, ~Effect of Formulation Factors on Penetration of Hydrocortisone through Mouse Skin~, Journal of Pharmaceutical Sciences, Vol. 67, No. 6 (June, 19~8), pp. ~89-792;
Cooper, E.R., ~Increased Skin Permeability for Lipophilic Mole-cules~, Journal of Pharmaceutical Sciences, Vol. 73, No. 8 (August, 1984), pp. 1153-1156; Aungst, 8.J., N. J. Rogers ~ E.
Shefter, ~Enhancement of Naloxone Penetration through Human Skin 1Q Vitro Using Fatty Acids, Fatty Alcohols, Surfactants, Sul-~oxides and Amides~, In~D~ion~l Journal of Pharmaceutics, Vol.
33 (1986), pp. 225-23~; Green, P.6., ~ J. Hadgraft, ~Facilitated Transfer of Cat10nic Drugs Across a Lipoidal Membrane by Oleic Ac~d and Lauric Acid~, Internation~l Journal of Pharmaceutics, Vol~ 37 (J~ly, 1987), pp. 251-255.
It is an object of the present invention to provide novel compositions for enhancing the skin penetratton of drugs.
It i s a further object of the present invention to provide such compositions which provide sufficient skin penetration enhancement to achieve therapeutic levels of the drugs in target internal tissues.
It is a further object of the present invention to provide such compositions with low dermal irritation, especially in compositions requiring a low pH.
It is a still further object of the present invention to provide such compositions having good stability and good cosmetics.
SUMMARY OF THE INVENTIQN
The present invention relates to pharmaceutical compositions for topical application having enhanced penetration through the skin comprising:
(a) a safe and effective amount of a pharmaceutical active;
and (b) from about 0.05% to about 20% of a non-ionic 3s ` polyacrylamide having a molecular wight of from about 1,000,000 to about 30,000,000.
W O 93/07902 ~12 ~ ~ ~ 7 P~/US92/08741 All concentrations and ratios herein ~re b~ ~ei~ht of tot~l co~positton and all measurements are at 25C, unless otherwise spec~fied.
~ETAILED DESCRIPTION QE THE INVENTION
The present invention involves compos~ttons compr1s~ng certain specif~c non-ionic polymers which may be ~pplied topic~lly to the skin and which result in improved transdermal penetration of the drugs through the skin. These compositions also have a high solvent tolerance, i.e.~ high level of solvents such as alcohol and other water-soluble componants which may be necessary to solubilize the active can be included in the compositions.
~rua Act~ve The compositions of the present invention comprise a safe and effective amount of a drug active. The phrase ~safe and effectiv~
amount~, as used herein, means an amount of a drug high enough to significantly positively modify the condition to be tre~ted, but low enough to avoid serious side effects (at a reasonable benefit/risk r~tio), within the scope of sound medical judgement.
A safe and ~ffective amount of the drug ~will vary with the spectfic drug, the ability of the composition to penetrate the drug through the skin, the ~mount of composition to be applied, the p~rticular condition being treated, the age and physical cond~tion of ~he patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent ther~py, and ljke factors.
~he drug compounds present in the compositions of the present invention preferably comprise from about O.lX to about 20%
by weight of the compositions, more preferably from aboutO.1% to about lOX~ and most preferably from about 0.1% to about 5%.
Mixtures of drug actives may also be used.
Useful drug actives in the compositions of the present invention include anti-acne drugs. Anti-acne drugs preferred for use in the present invention include the keratolytics such as salicylcic acid, sulfur, lactic acid, glycolic, pyruvic acid, 3; urea, resorcinol, and N-acetylcysteine; retinoids such as retinoic acid and its derivatives (e.g., cis and trans);
WO 93/07902 2 1 2 0 9 2 7 PCI`/US92/OX741 antibiotics and antimicrobials such as benzoyl peroxide, octopirox, erythromycin, tetracyclin, triclosan, azel aic acid and its derivatives, phenoxy ethanol and phenoxy proponol, ethylacetate, clindamycin and meclocycline; seb~stats such as flavinoids; hydroxy acids; and bile salts such as scymnol sulfate and its derivatives, deoxycholate, and cholate.
Useful drug actives in the compositions of the present invention include non-steroidal anti-inflammatory drugs (NSAIDS).
The NSAIDS can be selected from the following categories:
propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams.
All of these NSAIDS are fully described in the U.S. Patent 4,985,459 to Sunshine et al., issued January 15, 1991, incorporated by reference herein. Most preferred are the propionic NSAIDS including but not limited to aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, ~ uprofen and bucloxic acid. Also useful are the steroidal anti-inflammatory drugs including hydrocortisone and the like.
Useful drug actives in the compositions of the present invention include antihistaminic drugs. Antihistaminic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chlorpheniramine, triprolid~ne, diphenhydramine, doxylamine, pyrilamine, phenindamine, promethazine, cyproheptadine, azatadine, clemastine, carbinoxamine, tripelennamine, terfenadine, dexchlorpheniramine, brompheniramine, chlorcyclizine, diphenylpyraline, pheniramine and phenyltoloxamine, and mixtures thereof.
Useful drug actives in the compositions of the present invention include antitussive drugs. Antitussive drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of dextromethorphan, codeine, caramiphen and carbetapentane.
? WO 93/07902 . 212 0 9 2 7 PCI~/US92/08741 Useful dr~g actives in the compositions of the present invention include antipruritic drugs. Antipruritic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of methdilizine and trimeprazine.
Useful drug actives in the compositions of the present invention include anticholinergic drugs. Anticholinergic drugs preferred for inclusion in compositions of the present invention include phar~aceutically-acceptable salts of scopolamine, atropine, homatropine, levodopa, dicyclomine, hyoscyamine, procyclidine, trihexyphenidyl and ethopropaz~ne.
Useful drug actives in the compositions of the present invention include anti^emetic and antinauseant drugs. Anti-emetic and antinauseant drugs proferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of cyclizine, meclizine, chlorproma2ine, bucli2ine, metoclopramide, prochlorperazine and trimethobenza~ide.
Useful drug actives in the compositions of the present invention include anorexic drugs. Anorexic~drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of benzphetamine, phentermine, chlorphentermine, fenfluramine, diethylpropion and phendimetrazine.
Useful drug acttves in the compositions of the present invention include central stimulant drugs. Central stimulant drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of amphetamine, methamphetamine, dextroamphetamine and methylphenidate.
Useful drug actives in the compositions of the present invention include antiarrhythmic drugs. Antiarrhythmic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of propranolol, procainamide, disopyramide, quinidine, encainide, flecanaide, mexiletine and tocainide. Other antiarrhythmic drugs preferred for inclusion in compositions of the present invention include W O 93~07902 2~ 20 9~7 PCI/US92/08741 pharmaceutically-acceptable salts of th~ quinidine derivatives disclosed in U.S. Patent No. 4,716,171 issued to Jarreau and Koenig on December 29, 1987, which is hereby incorporated herein in its entirety by reference. Highly preferred compounds included in this class include pharmaceutically-acceptable salts of 3S-hydroxy-10,11-dihydroquinidine, 3R-hydroxy-10,11-dihydro-quinidine, 3R-hydroxy-O-acetyl-10,11-dihydroquinidine, and 3S-hydroxy-O-acetyl-10,11 -dihydroquinidine, especially 3S-hydroxy-10,11-dihydroquinidine.
Use~ul drug actives in the compositions of the present invention include ~-adrenergic blocker drugs. ~-Adrenergic blocker drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of metoprolol, acebutolol, betaxolol, labetalol and timolol.
~-Adrenergic blocker drugs more preferred for inclusion in compositions of the present invention include metoprolol tartrate, acebutolol hydrochloride, betaxolol hydrochloride, labetalol hydrochloride and timolol maleate.
Useful drug actives in the composit~ons of the present invention include cardiotonic drugs. Cardiotonic drugs preferred for inclusion in compositions of the present invention i,nclude pharmaceutically-acceptable salts of milrinone, amrinone and dobutamine. Other cardiotonic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of 14-amino steroid derivatives, some of which are disclosed in U.S. Patent Nos. 4,325,879, ~,552,868 and 4,584,289, issued to Jarreau and Koenig on April 20, 1982, November 12, 1985 and April 22, 1986, respectively, each of which are hereby incorporated herein in their entirety by reference.
Useful drug actives in the compositions of the present invention include antihypertensive drugs. Antihypertensive drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of enalapril, clonidine, ~5 hydralazine, minoxidil (whieh is also a hair growth stimulator ` ~ W O 93/07902 2 1 2 0 ~ 2 7 PCT/US92/08741 drugJ, guanadrel, guanethid1ne, guanfacine, mecamylamine, methyldopate, pargyline, phenoxybenzamine and prazosin.
Useful drug actives in the compositions of the present inventi~n include diuret k drugs. Diuretic drugs preferred for inclusion in compositions of the present invention include pharma-ceutically-acceptable salts of amiloride and hydrochlorothiazide.
Diuretic drugs more preferred for inclusion in compositions of the present invention include amiloride hydrochloride.
Usefut drug actives in the compositions of the present invent10n include vasod~lator drugs. Vasodilator drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of diltazem, amiodarone, isoxsuprine, nylidrin, tolazoline and verapamil.
Useful drug actives in the compositions of the present invention include vasoconstrictor drugs. Vasoconstrictor drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of dihydroergotamine, ergotamine and methysergide.
Useful drug actives in the compositions of the present invention includes anti-ulcer drugs. Anti-ulcer drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of ranitidine and cimetidine.
Useful drug actives in the composit~ons of the present invention inolude include anesthetic drugs. Anesthetic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of lidocsine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine and phenol.
Useful drug actives in the compositions of the present invention include ant~depressant drugs. Antidepressant drugs preferred fur inclusion in compositions of the present invention include pharmaceutically-acceptable salts of imipramine, desipramine, amitriptyline, nortriptyline, protriptyline, doxepin, maprotiline, phenelzine, tranylcypromine, trazodone and trimipramine.
WO 93~07902 2 ~-~ 9 ~ ~7 PCI /US92/08741 - 1 0 - .
Useful drug actives in the compositions of the present invention include tranquilizer and sedative drugs. Tranquilizer and sedative drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chlordiazepoxide, benactyzine, benzquinamide, flurazepam, hydroxyzine, loxapine and promazine.
Useful drug actives in the compositions of the present invention include antipsychotic drugs. Antipsychotic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chlorprothixene, fluphenazine, haloperidol, molindone, thioridazine and trifluoperazine.
Useful drug actives in the compositions of the present invention include antimicrobial drugs (antibaeterial, antifungal, antiprotozoal and antiviral drugs). Antimicrobial drugs preferred for inclusion in compositions of the present invention include phanmaceutically-acceptable salts of ~-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracyoline, clindamycin, ethambutol, metronidazole~ pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minooycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, micona~ole and amanfadine.
Antimicrobial drugs preferred for inclusion in compositions of the present invention include tetracycline hydrochloride, erythromycin estolate, erythromycin stearate (salt), amikacin sulfate, doxycyetine hydrochloride, capreomycin sulfate, chlorhexidine gluconate, ehlorhexidine hydrochloride, chlortetracycline hydro-chloride, oxytetracycline hydrochlaride, clindamycin hydro-chloride, ethambutol hydrochloride, metronidazole hydrochloride, pentamidine hydrochloride, gentamicin sulfate, kanamycin sulfate, lineomycin hydrochloride? methacycline hydrochloride, methenamine hippurate, methenamine mandelate, minocycline hydrochloride, neomycin sulfate, netilmicin sulfate, paromomycin sulfate.
streptomycin sulfate, tobramycin sulfate, miconazole hydrochloride, amanfadine hydrochloride, amanfadine sulfate~
`WO 93/07902 21 2 0 !3 2 7 PCl/US92/08741 triclosan, octopirox, parachlorometa xylenol, nystatin, tolnaftate and clotrimazole.
Useful drug actives in the compositions of the present invention include antineoplastic drugs. Antineoplastic drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of bleomycin, daunorubicin, doxorubicin, mechlorethamine, procarbazine, quinacrine, tamoxifen, vinblastine and vincristine.
Useful drug actives in the compositions of the present invention include antimalarial drugs. Antimalarial drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of chloroquine, hydroxychloroquine primaquine and quinine.
Useful drug actives in the compositions of the present invention include muscle relaxant drugs. Muscle relaxant drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of cinnamedrine, cyclobenzaprine, flavoxate, orphenadrine, papaverine, mebeverine, idaverine, ritodrine, dephenoxylate, dantrolene and azumolene.
Useful drug actives in the compositions of the present invention include antispasmodic drugs. Antispasmodic .drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of the compounds disclosed in U~S. Patent Number 3,856,825 issued to ~right, Burch and Goldenburg on December 24, 1974, which is hereby incorporated herein in its entirety by reference.
Useful drug actives in the compositions of the present invention include antidiarrheal drugs. Antidiarrheal drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of loperamide.
Useful drug actives in the compositions of the present invention include bone-active drugs. Bone-active drugs preferred for inclusion in compositions of the present invention include pharmaceutically-acceptable salts of diphosphonate drug compounds and phosphonoalkylphosphinate drug compounds, including the prodrug esters thereof. Such compounds are disclosed~ for 21209~
WO 93/0~902 - 1 2 - PCI~/US92J08741 exa~ple, in U.S. Patent Nos. 3,683,080 issued to francis on August 8, 1972; 4,304~734 issued to Jary, Rihakova ~ Zobacova on December 8, 1981; 4,687,768 issued to 8enedict ~ Johnson on August 18, 1987; 4,711,880 issU2d to Stahl ~ Schmitz on December 8, 1987; and 4,719,203 issued to Bosies h ~all on January 12, 1988; copending U.S. patent application Serial Nos. 808,584, of Benedict ~ Perkins filed December 13, 1985; 945,069 of Ebetino, Buckingham ~ McOsker filed Dece~ber 19, 1986; 945,068 of Ebetino ~ Benedict filed Dece~ber 19, lq86; and 069,666 of Ebetino filed July 6, 1987; and Europe~n Patent Application Hos. 0,001,584 o~ Blum, Hempel ~or~s, published May 2, 1979; 0,039,033 published April 11, 1981;
0,186,405 of Benedict ~ Perk~ns, published July 2, 1986; and 0,2~3,173 of Oku, Todo, Kasah-ra, Nakamura, Kayakiri ~ Hashimoto, published October 28, 1987; all of which are hereby incorporated herein in their entirety by reference.
Also useful in the present invention 2re sunless tanning agents including dihydroxyacetone, indole derivatives, and the like. These sunless tanning ag~nts ~ay also be used in co~binat~on with conventional sunscreen agents such as those disclosed in Segarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Tç~hnoloqY, incorporated by reference herein, as well as wound healing agents such as peptide derivatives, yeast, panthennl, Iamin and kinetin.
Other usefulskin actives include skin bleaching (or 1 ightening) agents incluJing but not 1 imited to hydroquinone, ascorbic acid, kojic acid and sodium metabisul~ite.
NQnionic Polvacrylamide The non-ionic polymers useful in the present invention are polyacrylamides and substituted polyacrylamides, branched or unbranched. These polymers are non-ionic water-dispersable polymers which can be formed from a variety of monomers inoluding acrylamide and methacrylamide which are unsubstituted or substituted with one or two alkyl groups (preferably Cl-Cs). Preferred acrylate amides and methacrylate amides in which the amide nitrogen is unsubstituted, or 3~ substituted with one or two Cl-Cs alkyl groups (preferably:
methyl, ethyl or propyl), for example, acrylamide, methacrylamide, (*See page 19 for equivalent~.) .- .. .
W O 93/07902 212 0 ~ 2 7 P~/US92~08741 N-methylacrylamide, N-methylmethacrylamide, N,N-dimethylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide and N,N-dimethylacrylamide. These monomers are senerally disclosed in U. S. Patent 4,963,348 to Bolich, Jr. et al., issued October 16, 1990, incorporated by reference herein in its entirety. These copolymers may optionally be for~ed using conventional neutral crosslinking agents such as dialkenyl co~4ounds. The use of such crossltnking agents for cat10nic polymers is disclosed in U.S. Patent ~,628,078 to Glover et al. issued December 9, 1986 and U.S. P~tent 4,599,379 to Flesh~r et al. issued July 8, 1986 both of ~h~ch are incorporated by reference herein. These non-ionic co-poly~ers have a molecular weight greater than about 1,000,000 preferably greater than about 1,500,000 and range up to about 30,000,000. Preferably, as a result of being synthesized by reverse phase emulsion polymerization, these non-ionic polyacrylamides are predispersed in a water-im~isc~ble solvent such as mlneral oil and the like~
containing a high HLB surfactant (HLB from about 7 to about 10) which helps to facilitate water dispersibility of the polyacrylamide. Most preferred for use herein is the non-ionic polymer under the ~TFA designation: polyacrylamide and isoparrafin and laureth-71 available as Sepigel from Seppic Corporation.
These non-ionic polyacrylamides are present at a level from about 0.05% to about 20%, preferably from about 0.05% to 5% and most preferably from about 0.1% to about lOX.
Vehiçle The compositions of the present invention are used atong with pharmaceutically-acceptable carrier (or vehicle) components. The term "pharmaceutically-acceptable carrier components~, as used herein, means compatlble solid or liquid filler diluents which are suitable for administration to a human or lower animal. The term ~compatible~, as used herein, means that the components are capable of being commingled with the drug compounds, diols and fatty acids of the compositions of the present invention, and with each other, in a manner such that 3~ there is no interaction which would substantially reduce the pharmaceutical efficacy of the compositions of the present WO 93/07902 P~/US92~08741 2120!~7 invention under ordinary use situations.
Pharmaceutically-acceptable carrier components must, of course, be of sufficiently high purity and sufficiently low toxicity to render them suitab1e for administration to the human or lower animal being treated.
Some examples of substances which can serve as pharmaceuti-cally-acceptable carrier components are polyethylene glycol;
glycerol; ethanol; water; antioxidants; surfactants; chelating agents; preservatives; thickeners; as well as other non-toxis com-patible substances used in pharmaceutical formulat~ons.
These compositions can also contain one or more humectants/moisturizers many of which may also be useful as pharmaceutical actives. A variety of humectants/moisturizers can be employed and can be present at a level of from about 1% to about 30%, more preferably from about 2% to about 8% and most preferably from about 3X to about 5%. These materials include polyhydroxy alcohols such as sorbitol, glycerin, hexanetriol, propylene glycol, hexylene glycol and the like; polyethylene glycol; sugars and starches; sugar and starch deriYatives (e.g.
alkoxylated glucose)~ D-panthenol; hyaluronic acid; lactamide monoethanolamine; acetamide monoethanolamine; and mixtures thereof.
Preferr~d humectants/moisturizers for use in the compositions of the present in~ention are the C3-C6 diols and triols.
Especially preferred is the triol, glycerin. The compositions of this invention may also contain pharmaceutically acceptable optional components that modify the physical and/or therapeutic effects of the compositions~ Such optional components may include, for example, additional solvents, emulsifiers, gelling agents, fragrances, preservatives, and stabilizers. However, such optional materials must not unduly interfere with the transdermal delivery of the drug active. Optional components useful in the compositions of this invention are described in the following patent documents, incorporated by reference herein: European Patent Publieation 43,738, Wickett et al., published January 13, WO 93/07902 212 0 ~ 2 7 PCI~/US92/08741 1982; and U.S. Patent 4,552,872, Cooper et al., issued November 12, 1985.
Most preferred compositions herein are gel-type compositions.
Another optional material is a solvent or co-solvent material. Such solYent materials include, for example, short chain alcohols and ethers. Preferred optional solvent materials include polyethylene glycols, dipropylene glycol, ethylene glycol monoethyl ether, ethanol, isopropanol, and dimethyl isosorbide.
~ater may also be used as a solvent or co-solvent in the compositions of this inven~ion. I~ water is used in a saturated system, a gel or emulsion is preferably formed.
Most preferred compositions have a pH of below about 5, preferably below about 4, and most preferably below about 3.
While particular embodiments of the present invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the compositions d1s-closed herein can be made without departing from the spirit and the scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of this invention.
Test Method Transdermal penetration of drugs is convenieotly determined and compared from various vehicles using the apparatus and procedure described below.
Full thickness excised human thigh skin is obtained from cadavers after all hair had been clipped and the skin washed. The skin samples are then bathed in 10% glycerin and stored frozen.
The glycerin prevents the formation of ice crystals which could possibly damage the keratinized cells and/or the intercellular lipid matrix. After a rapid thawing, the skin is conditioned for 24 hours in Hank's Balanced Salt Solution with 1%
antibacterial-antimycotic solution. Then the skin is washed with distilled water. A single skin donor is used for each experiment, and individual sections for use are selected based on integrity of the stratum corneum (visual determination). Selected areas are cut to 1cm2 using a scalpel.
WOg3~07gO2 -16- PCI~/USg2/08741 Tests are conducted using glass diffusion cells placed 1n temperature-regulated stirring modules- Skin sections are mounted in the cells, and the receptor phase is added. The receptor phase is SOX Hank's Balance Salt Solution with 1% antibiotic-antimycot;c solution. Each diffusion cell has an exposed are~ of 0.79cm2 and a receptor capacity of Sml. Sufficient formulation is applied (750ul) to the surface of the skin to ensure infinite dose conditions, and the diffusion cell is covered with plastic wrap or parafilm to prevent product evaporation. At each sampling time the receptor phase is removed for analysis of drug content. The receptor phase is removed for analysis of drug content. The receptor phase is replenished at each sampling time in order to maintain sink conditions. Preferably 3 to 6 replicates are run with sa~pling intervals occurring at l, 2, 4 ~ 6 hours.
Penetration rate (Flux) is deter~ined as the quantity of drug penetrating a measured area of skin per hour during the S hour interval between l hour and 6 hours. Generally steady state is reached before 1 hour. Penetration rate is usually expressed as ug drug per cm2 skin per hour.
The following examples further describe and demonstrate embodiments within the scope of the present invention.. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention.
Ingredients are identified by chemical or CTFA name.
WO 93~07902 PCI/US92~08741 212 0 !~ 2 7 "
E~AMPLES
ExamPle I
An anti-acne composition is made by combining the following ingredients.
In~ edient (YOW~W?
~ater, Purified 52.395 Alcohol SDA 40 40.000 Polyacrylamide and C13 14 Isoparaffin and Laureth-7 4.000 Salicylic Acid 2.000 Glycerin 1.000 Aloe Vera Gel 0.500 Menthol 0.100 Disod~um EDTA 0.005 ~he alcohol is added to a suitable si~e container. Using a Lightnint ~ixer with a 3 blade paddle prop, the salicylic acid is added to the alcohol and mixed at low speed (100 rpm) until the salicylic acid is dissolved. Menthol is added to the alcohol and mixed until dissolved. Separately, water is added to a su~table size container. Aloe vera gel and disodium EDTA are added to the water and mixed at low speed (100 rpm) until completely dissolved.
The water phase is then added to the alcohol phase and mixed until clear. Gylcerin is added and mixed until clear. While mixing at moderate speed (300 rpm~, the polyacrylamide and C13 14 isopara~fin and laureth-7 is added to form a gel. The resulting gel is mixed at moderate speed until uniform.
An anti-acne and/or analgesic composition is made by combining the following ingredients utilizing conventional mixing techniques as described above in Example I.
3~
Inaredient ~%W/~
Water, Purified 55.0 Ibuprofen 2.0 Alcohol SDA 40 40.0 Polyacrylamide and C13 l4 Isoparaffin and Laureth-7 ~.0 The compositions display skin penetration of the Ibuprofen active as well as improved skin feel and residue characteristics together with excellent moisturizing, e~olliency, rub-in and absorption characterist~cs.
ExamDle III
A keratotytic composition for dermatological disorders is made by combining the following ingredients utilizing conventional mixing techniques as described above in Example I.
: Inaredient (%~
Water 86.5 - Urea 10.0 Benzyl Alcohol 0.5 Polyacrylamide and C13 14 Isoparaffin and Laureth-7 3~0 The compositions display skin penetration of the Urea active as well as improved skin feel and residue characteristics together with excellent moisturizing, emolliency, rub-in and absorption characteristics.
ExamDle IV
A composition for sunless tanning is made by combining the following ingredients utilizing conventional mixing techniques as described above in Example 1.
' ~ 35 ~, :~
.
` W O 93/07902 2 1 2 g 9 2 7 P ~ /US92/08741 ,Inqredient (YOW/W) Water 91.5 Benzyl Alcohol 0.5 Polyacrylamide and C13 14 Isoparaffin and Laureth-7 3.0 Dihydroxyacetyone 3.Q
Glycerin 2.0 Th~ compositions display improved skin penetration of the dihydroxyacetone as well as improved skin feel and residue charac-teristics together with excellent moisturizing, emolliency, rub in and absorption character~stics.
(*~quivalents: USSN 808584 equivale~t to US Patent 4,90~,679;
USSN 945069 equivalent to US Patent 4,868,164; USS~ 945068 equivalent to EP Patent 0,274,158; and ~SS~ 069666 equivalen$ to EP ~ppln. 298,553.)
Claims (7)
1. A topical pharmaceutical composition having enhanced penetration through the skin comprising:
(a) a safe and effective amount of a pharmaceutical active;
and (b) from 0.05% to 5% of a non-ionic polyacrylamide having a molecular wight of from 1,000,000 to 30,000,000.
(a) a safe and effective amount of a pharmaceutical active;
and (b) from 0.05% to 5% of a non-ionic polyacrylamide having a molecular wight of from 1,000,000 to 30,000,000.
2. The composition of Claim 1 wherein the polyacrylamide comprises monomers selected from acrylamide and methacrylamide which are unsubstituted or substituted with at least one alkyl group having from 1 to 5 carbon atoms, preferably wherein the polyacrylamide comprises monomers selected from the group consisting of acrylamide, methacrylamide, N-methylacrylamide, N-methylmethacrylamide, N,N-dimethylmethacrylamide, N-isopropylacrylamide, N-isopropylmethacrylamide and N,N-dimethylacrylamide, and more preferably wherein the polyacrylamide has a molecular weight greater than 1,500,000.
3. The composition of Claim 2 wherein said pharmaceutical active is selected from the group consisting of ant-acne drugs, non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, sunless tanning agents; sunscreen agents, wound healing agents, skin bleaching or lightening agents, antihistaminic drugs, antitussive drugs, antipruritic drugs, anticholinergic drugs, anti-emetic and antinauseant drugs, anorexic drugs, central stimulant drugs, antiarrhythmic drugs, .beta.-adrenergic blocker drugs, cardiotonic drugs, antihypertensive drugs, diuretic drugs, vasodilator drugs, vasoconstrictar drugs, anti-ulcer drugs, anesthetic drugs, antidepressant drugs, tranquilizer and sedative drugs, antipsychotic drugs, antimicrobial drugs, antineoplastic drugs, antimalarial drugs, muscle relaxant drugs, antispasmodic drugs, antidiarrheal drugs and bone-active drugs and mixtures thereof.
4. The composition of Claim 5 herein said pharmaceutical active is an acne active selected from the group consisting of salicylcic acid, sulfur, resorcinol, N-acetylcysteine, octopirox, retinoic acid and its derivatives, benzoyl peroxide, erythromycin, tetracyclin, azelaic acid and its derivatives, phenoxy ethanol and phenoxy proponol, ethylacetate, clindamycin and meclocycline, flavinoids, lactic acid, glycolic acid, pyruvic acid, urea, scymnol sulfate and its derivatives, deoxycholate and cholate and mixtures thereof.
5. The composition of Claim 3 wherein said antihistaminic drug is selected from the group consisting of chlorpheniramine maleate, chlorpheniramine tannate, triprolidine hydrochloride, triprolidine oxalate, diphenhydramine hydrochloride, diphen-hydramine ascorbate, diphenhydramine citrate, doxylamine suc-cinate, pyrilamine maleate, pyrilamine hydrochloride, pyrilamine tannate, phenindamine tartrate, promethazine hydrochloride, cyproheptadine hydrochloride, azatadine maleate, clemastine fumarate, carbinoxamine maleate, carbinoxamine hydrochloride, tripelennamine hydrochloride, tripelennamine citrate, dexchlorpheniramine maleate, brom-pheniramine maleate and chlorcyclizine hydrochloride and mixtures thereof; wherein said antitussive drug is selected from the group consisting of dextromethorphan hydrobromide, carbetapentane citrate, codeine phosphate and codeine N-oxide hydrochloride and mixtures thereof; wherein said anticholinergic drug is selected from the group consisting of scopolamine hydrobromide, scopolamine hydrochloride, atropine sulfate, atropine mucate, homatropine hydrobromide and homatropine hydrochloride and mixtures thereof; wherein said anti-emetic or antinauseant drug is selected from the group consisting of cyclizine hydrochloride, meclizine hydrochloride, chlorpromazine hydrochloride and chlorpromazine maleate and mixtures thereof; wherein said anorexic drug is selected from the group consisting of benzphetamine hydrochloride, phentermine hydrochloride, chlorphentermine hydrochloride and fenfluramine hydrochloride and mixtures thereof; wherein said antimicrobial drug is selected from the group consisting of .beta.-lactam drugs, quinolone drugs, ciprofloxacin, norfloxacin, tetracycline, erythromycin, amikacin, triclosan, doxycycline, capreomycin, chlorhexidine, chlortetracycline, oxytetracycline, clindamycin, ethambutol, metronidazole, pentamidine, gentamicin, kanamycin, lineomycin, methacycline, methenamine, minocycline, neomycin, netilmicin, paromomycin, streptomycin, tobramycin, miconazole and amanfadine, pharmaceutically-acceptable salts thereof and mixtures thereof; wherein said antiarrhythmic drug is selected from the group consisting of propranolol hydrochloride, procainamide hydrochloride, quinidine sulfate and quinidine gluconate and mixtures thereof; wherein said antihypertensive drug is selected from the group consisting of enalapril maleate, clonidine hydrochloride, hydralazine hydrochloride and hydralazine sulfate and mixtures thereof; wherein said anesthetic or antipruritic drug is selected from the group consisting of lidocaine hydrochloride, bupivacaine hydro-chloride, chlorprocaine hydrochloride, dibucaine hydrochloride, etidocaine hydrochloride, mepivacaine hydro-chloride, tetracaine hydrochloride, dyclonine hydrochloride and hexylcaine hydrochloride and mixtures thereof; wherein said bone-active drug is selected from the group consisting of 6-amino-1-hydroxy-hexane-1,1-diphosphonic acid, 3-amino-1-hydroxy-propane-1,1-diphosphonic acid, octahydro-1-pyridine-6,6-diphosphonic acid, 2-(2'-piperi-dinyl)-ethane-1,1-diphosphonic acid; 2-(3'-piperi-dinyl)-ethane-1,1-diphosphonic acid; 2-(2'-piperidinyl)-1-hydroxy-ethane-1,1-diphosphonic acid; 2-(3'-piperidinyl)-1-hydroxy-ethane-1,1-diphosphonic acid;
N-(2'-(3'-methyl)-piperidinylidene)-amino-methane diphosphonic acid; N-(2'-(1',3'-diazinylidene))-aminomethane diphosphonic acid; and N-(2-(3-methylpiperidinylidene))-aminomethane-phosphonomethylphosphinic acid, or esters thereof and mixtures thereof; and wherein said non-steroidal anti-inflammatory drug is selected from the group consisting of propionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives, and oxicams and mixtures thereof; preferably wherein said non-steroidal anti-inflammatory drug is a propionic acid derivatives selected from the group consisting of aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid and mixtures thereof.
N-(2'-(3'-methyl)-piperidinylidene)-amino-methane diphosphonic acid; N-(2'-(1',3'-diazinylidene))-aminomethane diphosphonic acid; and N-(2-(3-methylpiperidinylidene))-aminomethane-phosphonomethylphosphinic acid, or esters thereof and mixtures thereof; and wherein said non-steroidal anti-inflammatory drug is selected from the group consisting of propionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives, and oxicams and mixtures thereof; preferably wherein said non-steroidal anti-inflammatory drug is a propionic acid derivatives selected from the group consisting of aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid and mixtures thereof.
6. The composition of Claim 3 wherein said drug active is a sunless tanning agent selected from the group consisting of dihydroxyacetone, indole derivatives and mixtures thereof.
7. The composition of Claim 6 which further comprises a sunscreen active.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77842491A | 1991-10-16 | 1991-10-16 | |
| US07/778,424 | 1991-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2120927A1 true CA2120927A1 (en) | 1993-04-29 |
Family
ID=25113308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002120927A Abandoned CA2120927A1 (en) | 1991-10-16 | 1992-10-13 | Enhanced skin penetration system for improved topical delivery of drugs |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US5773023A (en) |
| EP (1) | EP0608320B1 (en) |
| JP (1) | JPH07500113A (en) |
| CN (1) | CN1072863A (en) |
| AT (1) | ATE162725T1 (en) |
| AU (1) | AU675211B2 (en) |
| BR (1) | BR9206632A (en) |
| CA (1) | CA2120927A1 (en) |
| CZ (1) | CZ85994A3 (en) |
| DE (1) | DE69224294T2 (en) |
| ES (1) | ES2114569T3 (en) |
| FI (1) | FI941771A (en) |
| HU (1) | HUT74560A (en) |
| MA (1) | MA22680A1 (en) |
| PT (1) | PT100963A (en) |
| SK (1) | SK43294A3 (en) |
| WO (1) | WO1993007902A1 (en) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ90494A3 (en) * | 1991-10-16 | 1994-07-13 | Richardson Vicks | Skin care preparation having the form of aqueous gel |
| BR9206632A (en) * | 1991-10-16 | 1995-04-25 | Richardson Vicks Inc | Improved skin penetration system for improved topical drug release |
| EG20380A (en) | 1991-10-16 | 1999-02-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
| AU4673993A (en) * | 1992-07-28 | 1994-02-14 | Procter & Gamble Company, The | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
| US5989536A (en) * | 1993-07-03 | 1999-11-23 | The Procter & Gamble Company | Personal cleansing compositions containing alkoxylated ether and cationic ammonium salt for deposition of active agent upon the skin |
| ZA947912B (en) * | 1993-10-12 | 1995-05-24 | Broadbent J W Nominees Pty Ltd | Treatment of medical disorders associated with free radical formation |
| WO1995026782A1 (en) * | 1994-03-30 | 1995-10-12 | Alza Corporation | Reduction of skin irritation during electrotransport delivery |
| FR2728793A1 (en) * | 1994-12-28 | 1996-07-05 | Oreal | Compsns. for treating sensitive skin |
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| CA2154979A1 (en) * | 1995-07-28 | 1997-01-29 | Kenneth T. Armstrong | Topical phenylephrine preparation |
| SE9601528D0 (en) | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as an antitissue agent |
| US5741500A (en) | 1996-07-15 | 1998-04-21 | Yates; Alayne | Gum growth pad |
| NL1003992C2 (en) * | 1996-09-10 | 1998-03-11 | Stein Gerrit Cornelis Johan | Therapeutic gel composition for skin treatment |
| US6165484A (en) * | 1997-08-26 | 2000-12-26 | Wake Forest University | EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections |
| US6294188B1 (en) | 1998-07-09 | 2001-09-25 | Aviana Biopharm Inc. | Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women |
| HUP0102741A3 (en) * | 1998-10-23 | 2002-12-28 | Idea Ag | Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates |
| SI1031347T1 (en) | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
| PT1031346E (en) | 1999-01-27 | 2002-09-30 | Idea Ag | NOT INVASIVE VACCINATION THROUGH SKIN |
| US6444647B1 (en) | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
| US6319510B1 (en) | 1999-04-20 | 2001-11-20 | Alayne Yates | Gum pad for delivery of medication to mucosal tissues |
| FR2795325A1 (en) * | 1999-06-24 | 2000-12-29 | B F B | Topical compositions contain erythromycin and a dicarboxylic acid, for the treatment of acne |
| WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
| US6147102A (en) * | 1999-10-26 | 2000-11-14 | Curatek Pharmaceuticals Holding, Inc. | Clonidine preparations |
| AU2005202737B2 (en) * | 1999-12-22 | 2009-01-22 | Bayer Innovation Gmbh | Use of chemotherapeutic agents |
| US7557235B2 (en) | 2000-02-16 | 2009-07-07 | Lubrizol Advanced Materials, Inc. | Hydroxyl-terminated thiocarbonate containing compounds, polymers, and copolymers, and polyurethanes and urethane acrylics made therefrom |
| WO2001080827A2 (en) * | 2000-04-21 | 2001-11-01 | Nature's Cure | Salicylic acid acne spray formulations and methods for treating acne with same |
| GB0010757D0 (en) | 2000-05-05 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
| FR2810883B1 (en) | 2000-06-28 | 2006-07-28 | Seppic Sa | NOVEL AUTOINVERSIBLE INVERSE LATEX ON FATTY ACID ESTERS, COSMETIC, DERMOCOSMETIC, DERMOPHARMACEUTICAL OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| US6576702B2 (en) | 2000-07-20 | 2003-06-10 | Noveon Ip Holdings Corp. | Plasticized waterborne polyurethane dispersions and manufacturing process |
| US20020193321A1 (en) * | 2000-12-12 | 2002-12-19 | Mohan Vishnupad | Dual dispenser for aesthitically acceptable delivery of anhydrous skin treatment compositions |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| US20030060422A1 (en) | 2001-08-31 | 2003-03-27 | Balaji Venkataraman | Tannate compositions and methods of treatment |
| GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| US6986895B2 (en) | 2001-09-12 | 2006-01-17 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Thickened cosmetic compositions |
| US20030118620A1 (en) * | 2001-09-12 | 2003-06-26 | Unilever Home & Personal Care Usa, Division Of Conopco Inc. | Thickener system for cosmetic compositions |
| US20030064084A1 (en) * | 2001-09-24 | 2003-04-03 | Bradley Pharmaceuticals, Inc. | Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use |
| US7022342B2 (en) | 2002-03-28 | 2006-04-04 | Andrx Corporation, Inc. | Controlled release oral dosage form of beta-adrenergic blocking agents |
| US7358295B2 (en) * | 2002-04-05 | 2008-04-15 | Lubrizol Advanced Materials, Inc. | Hybrid polymer composition, and article therefrom |
| US6897281B2 (en) * | 2002-04-05 | 2005-05-24 | Noveon Ip Holdings Corp. | Breathable polyurethanes, blends, and articles |
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| PT1509256E (en) | 2002-05-24 | 2009-10-15 | Angiotech Int Ag | Compositions and methods for coating medical implants |
| US20050209428A1 (en) * | 2002-06-19 | 2005-09-22 | Krishnan Tamareselvy | Breathable polyurethanes, blends, and articles |
| US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
| AU2003251875A1 (en) * | 2002-07-15 | 2004-02-02 | Combinatorx, Incorporated | Combination therapy for the treatment of neoplasms |
| US20040043946A1 (en) * | 2002-09-03 | 2004-03-04 | Popp Karl F. | Topical formulations for treatment of skin disorders |
| US20040171561A1 (en) * | 2002-09-03 | 2004-09-02 | Popp Karl F. | Topical formulations for treatment of rosacea |
| US20040167223A1 (en) * | 2002-09-03 | 2004-08-26 | Popp Karl F. | Topical antibacterial formulations |
| US7378479B2 (en) * | 2002-09-13 | 2008-05-27 | Lubrizol Advanced Materials, Inc. | Multi-purpose polymers, methods and compositions |
| US20040241130A1 (en) * | 2002-09-13 | 2004-12-02 | Krishnan Tamareselvy | Multi-purpose polymers, methods and compositions |
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| WO2004069221A1 (en) * | 2003-02-03 | 2004-08-19 | Warner-Lambert Company Llc | Improved formulation for skin-lightening agents |
| PT1644024T (en) | 2003-06-06 | 2019-10-24 | Univ Texas | Antimicrobial flush solutions |
| FR2856691B1 (en) | 2003-06-26 | 2005-08-26 | Seppic Sa | NOVEL POWDER POLYMER, PROCESS FOR PREPARING THE SAME, AND USE AS THICKENING |
| US7776355B2 (en) * | 2003-07-03 | 2010-08-17 | Medics Pharmaceutical Corporation | Delivery system for topical medications |
| US20050025817A1 (en) * | 2003-07-03 | 2005-02-03 | Bhatia Kuljit S. | Delivery system for topical medications |
| US20060229258A1 (en) * | 2003-07-30 | 2006-10-12 | Daniela Serikaku | Steroidal compositions containing hydroxycarboxylic acids and methods of using the same |
| FR2861397B1 (en) | 2003-10-22 | 2006-01-20 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | NEW CONCENTRATED REVERSE LATEX, PROCESS FOR PREPARATION AND USE IN INDUSTRY |
| US20050226920A1 (en) * | 2004-04-13 | 2005-10-13 | Kirk Voelker | Method of decreasing nicotine withdrawal symptoms during smoking cessation. |
| US7479289B2 (en) * | 2004-07-02 | 2009-01-20 | Medicis Pharmaceutical Corporation | Stable cleanser compositions containing sulfur |
| US7655682B2 (en) | 2004-07-02 | 2010-02-02 | Medicis Pharmaceutical Corporation | Triple anti-irritant composition |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| EP1786848A1 (en) | 2004-08-06 | 2007-05-23 | Noveon, Inc. | Polyurethanes and urethane acrylics made from hydroxyl-terminated thiocarbonate containing compounds |
| US8137754B2 (en) * | 2004-08-06 | 2012-03-20 | Lubrizol Advanced Materials, Inc. | Hydroxyl-terminated thiocarbonate containing compounds, polymers, and copolymers, and polyurethanes and urethane acrylics made therefrom |
| KR20070086045A (en) * | 2004-11-12 | 2007-08-27 | 이데아 아게 | Extended surface aggregates in the treatment of skin conditions |
| FR2879607B1 (en) | 2004-12-16 | 2007-03-30 | Seppic Sa | NOVEL CONCENTRATED REVERSE LATEX, PROCESS FOR PREPARING THE SAME, AND USE IN INDUSTRY |
| WO2006081518A2 (en) * | 2005-01-28 | 2006-08-03 | Collegium Pharmaceutical, Inc. | Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents |
| TW200722087A (en) * | 2005-03-30 | 2007-06-16 | Astion Dev As | Treatment of dermatological diseases and pruritus |
| US20060223786A1 (en) * | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
| FR2886851B1 (en) * | 2005-06-10 | 2007-10-05 | Galderma Sa | COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA |
| US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
| US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7541347B2 (en) * | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
| US7544373B2 (en) * | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20100278759A1 (en) * | 2006-02-08 | 2010-11-04 | Howard Murad | Topical Therapeutic Delivery System |
| EP1998742A2 (en) * | 2006-03-08 | 2008-12-10 | Nuviance, INC. | Transdermal drug delivery compositions and topical compositions for application on the skin |
| ES2560540T3 (en) | 2006-03-31 | 2016-02-19 | Stiefel Research Australia Pty Ltd | Foamable suspension gel |
| US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
| US8323672B2 (en) | 2006-08-29 | 2012-12-04 | Karykion Corporation | Method of removing ticks from the skin and reducing the risk of bites |
| US7604814B2 (en) * | 2006-08-29 | 2009-10-20 | Karykion Inc. | Method of removing ticks from the epidermal tissue of humans and other mammals |
| CN101535240B (en) | 2006-10-02 | 2015-07-22 | 于崇曦 | Positively charged water-soluble prodrugs of prostaglandins and related compounds with fast skin penetration rate |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| JP5424887B2 (en) | 2006-11-08 | 2014-02-26 | チョンシー ユー | Transdermal delivery system for peptides and related compounds |
| ES2547258T3 (en) | 2006-12-10 | 2015-10-02 | Chongxi Yu | Systems of transdermal administration of beta-lactam antibiotics |
| HUE031712T2 (en) | 2007-01-15 | 2017-08-28 | Chongxi Yu | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
| JP5389668B2 (en) | 2007-01-31 | 2014-01-15 | チョンシー ユー | Positively charged water-soluble prodrugs of 1H-imidazo [4,5-c] quinolin-4-amine and related compounds with very high skin permeability |
| US20080188446A1 (en) * | 2007-02-02 | 2008-08-07 | Warner Chilcott Company Inc. | Tetracycline compositions for topical administration |
| WO2008097850A1 (en) * | 2007-02-02 | 2008-08-14 | Warner Chilcott Company, Inc. | Tretracycline compositions for topical administration |
| US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
| JP2010529101A (en) | 2007-06-04 | 2010-08-26 | テックフィールズ インコーポレイテッド | NSAIA prodrug with very fast skin and membrane permeation rate and novel pharmaceutical use thereof |
| US20100105750A1 (en) * | 2008-10-23 | 2010-04-29 | Nycomed Us Inc. | Stable metronidazole gel formulations |
| US20100221313A1 (en) * | 2008-12-01 | 2010-09-02 | Innovative Pharmaceuticals, Llc | Transdermal reservoir patch |
| WO2010065936A1 (en) | 2008-12-04 | 2010-06-10 | Chongxi Yu | High penetration compositions and their applications |
| WO2010105050A1 (en) | 2009-03-11 | 2010-09-16 | Isp Investments Inc. | Thickening additive compositions |
| FR2943677B1 (en) * | 2009-03-31 | 2012-10-26 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | NEW THICKENING POLYMER IN POWDER FORM |
| US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
| RU2627065C2 (en) | 2009-05-08 | 2017-08-03 | Текфилдз Байокем Ко., Лтд. | Prodrug compositions with high degree of penetration based on peptides and related compounds |
| US9969751B2 (en) | 2009-06-10 | 2018-05-15 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds |
| CN102008730B (en) * | 2009-09-08 | 2012-07-04 | 中国科学院理化技术研究所 | Transdermal medicine composition and transdermal medicine kit |
| US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
| ES2700148T3 (en) | 2012-03-09 | 2019-02-14 | Covestro Deutschland Ag | Aqueous polyurethane dispersion for the treatment of acne |
| RU2683934C2 (en) | 2012-05-16 | 2019-04-03 | Текфилдз Фарма Ко., Лтд. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
| FR2992323B1 (en) | 2012-06-25 | 2015-07-03 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | NEW SURFACE-FREE REVERSE LATEX FREE OF SURFACTANT, ITS USE AS A THICKENING AGENT IN A COSMETIC COMPOSITION |
| US8936814B2 (en) * | 2012-11-30 | 2015-01-20 | Zuri A. Murrell | Skin cream |
| TWI593411B (en) | 2013-04-30 | 2017-08-01 | 徐懷山 | Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease |
| FR3011464B1 (en) | 2013-10-07 | 2015-11-20 | Snf Sas | COSMETIC USE OF POLYMERS OBTAINED BY LOW CONCENTRATION REVERSE EMULSION POLYMERIZATION WITH A LOW RATE OF NEUTRALIZED MONOMERS |
| FR3024736B1 (en) | 2014-08-06 | 2016-08-26 | Snf Sas | USE IN DETERGENT COMPOSITIONS OF POLYMERS OBTAINED BY LOW-CONCENTRATION REVERSE EMULSION POLYMERIZATION WITH A LOW RATE OF NEUTRALIZED MONOMERS |
| US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
| JP6891118B2 (en) | 2014-12-23 | 2021-06-18 | インテレクチュアル プロパティ アソシエイツ エルエルシーＩｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ａｓｓｏｃｉａｔｅｓ， ＬＬＣ | Methods and formulations for transdermal administration |
| US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
| US10413505B1 (en) | 2017-02-07 | 2019-09-17 | Genus Lifesciences Inc. | Pharmaceutical compositions and methods of using the same |
| US10149843B1 (en) | 2017-02-07 | 2018-12-11 | Gneus Lifescineces Inc. | Pharmaceutical compositions and methods of using the same |
| US10231961B1 (en) | 2017-02-07 | 2019-03-19 | Genus Lifesciences Inc. | Pharmaceutical compositions and methods of using the same |
| US10758329B1 (en) | 2019-08-20 | 2020-09-01 | Raymond L. Wright, III | Hydrating mouth guard |
| CN113143845A (en) * | 2020-10-13 | 2021-07-23 | 西北师范大学 | Acrylamide-propranolol hydrochloride hydrogel and preparation method thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US128474A (en) * | 1872-07-02 | Improvement in stove-pipe thimbles | ||
| USRE28474F1 (en) * | 1970-12-15 | 1983-12-20 | Nalco Chemical Co | Process for rapidly dissolving water-soluble polymers |
| US3624019A (en) * | 1970-12-15 | 1971-11-30 | Nalco Chemical Co | Process for rapidly dissolving water-soluble polymers |
| US3920808A (en) * | 1973-05-08 | 1975-11-18 | Univ Minnesota | Method of protecting human skin from actinic radiation |
| US3920810A (en) * | 1974-04-23 | 1975-11-18 | Burton Parsons And Company Inc | Polyacrylamide containing ophthalmic solutions |
| US4039501A (en) * | 1975-05-30 | 1977-08-02 | National Patent Development Corporation | Plasticized hydrophilic polymers |
| US4675009A (en) * | 1977-11-07 | 1987-06-23 | Lec Tec Corporation | Drug dispensing device for transdermal delivery of medicaments |
| US4307717A (en) * | 1977-11-07 | 1981-12-29 | Lectec Corporation | Sterile improved bandage containing a medicament |
| US4355028A (en) * | 1978-04-04 | 1982-10-19 | Westwood Pharmaceuticals, Inc. | Composition for treating acne vulgaris |
| US4318907A (en) * | 1978-04-04 | 1982-03-09 | Westwood Pharmaceuticals, Inc. | Method for treating acne vulgaris and compositions useful for that purpose |
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| JPS596287B2 (en) * | 1980-11-28 | 1984-02-10 | 日東電工株式会社 | pharmaceutical formulations |
| US4938951A (en) * | 1980-12-30 | 1990-07-03 | Union Carbide Chemicals And Plastics Company Inc. | Potentiation of topical compositions wherein a uniform microdispersion of active agent is formed |
| AU8409582A (en) * | 1981-06-15 | 1982-12-23 | Alcon Laboratories, Inc. | Urea and carboxyvinyl polymers gel compositions |
| US4478853A (en) * | 1982-05-17 | 1984-10-23 | S. C. Johnson & Son, Inc. | Skin conditioning composition |
| US4540568A (en) * | 1982-10-14 | 1985-09-10 | Trager Seymour F | Injectionable viscoelastic ophthalmic gel |
| US4948576A (en) * | 1983-02-18 | 1990-08-14 | Johnson & Johnson Consumer Products, Inc. | Detergent compositions |
| US4650827A (en) * | 1983-11-02 | 1987-03-17 | Allied Corporation | Stable water-in-oil emulsions |
| GB8401206D0 (en) * | 1984-01-17 | 1984-02-22 | Allied Colloids Ltd | Polymers and aqueous solutions |
| GB8414950D0 (en) * | 1984-06-12 | 1984-07-18 | Allied Colloids Ltd | Cationic polyelectrolytes |
| GB8416453D0 (en) * | 1984-06-28 | 1984-08-01 | Allied Colloids Ltd | Aqueous polymer dispersions |
| US5017367A (en) * | 1984-10-01 | 1991-05-21 | Stojkoski Radmila G | Skin treatment preparation |
| US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
| US4806345C1 (en) * | 1985-11-21 | 2001-02-06 | Johnson & Son Inc C | Cross-linked cationic polymers for use in personal care products |
| GB8531118D0 (en) * | 1985-12-18 | 1986-01-29 | Allied Colloids Ltd | Copolymers |
| US5200448A (en) * | 1986-01-03 | 1993-04-06 | Exxon Chemical Patents Inc. | Freeze-thaw stable polyacrylamide emulsions |
| US5057566A (en) * | 1986-02-19 | 1991-10-15 | Nippon Zeon Co., Ltd. | Thermoplastic rubber compositions |
| US4731242A (en) * | 1986-03-21 | 1988-03-15 | Victor Palinczar | Waterproof sunscreen compositions |
| US4704436A (en) * | 1986-05-02 | 1987-11-03 | Barabas Eugene S | Water soluble complex of a poly(vinylpyrrolidone) copolymer and α-methyl-(2-methylpropyl)benzene acetic acid |
| IE60941B1 (en) * | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
| US4837019A (en) * | 1986-08-11 | 1989-06-06 | Charles Of The Ritz Group Ltd. | Skin treatment composition and method for treating burned skin |
| US5183664A (en) * | 1986-09-20 | 1993-02-02 | Smith And Nephew Associated Companies P.L.C. | Thin film adhesive dressings preparation and use |
| GB8622797D0 (en) * | 1986-09-22 | 1986-10-29 | Allied Colloids Ltd | Polymeric particles |
| EP0262945B1 (en) * | 1986-10-01 | 1994-01-05 | Ciba Specialty Chemicals Water Treatments Limited | Water soluble polymeric compositions |
| US5422118A (en) * | 1986-11-07 | 1995-06-06 | Pure Pac, Inc. | Transdermal administration of amines with minimal irritation and high transdermal flux rate |
| US4885161A (en) * | 1987-03-11 | 1989-12-05 | Medi-Tech International Corporation | Wound dressings in gelled paste form |
| US4929577A (en) * | 1987-03-11 | 1990-05-29 | Medi-Tech International Corporation | Transparent wound dressings in sheet form |
| US5059189A (en) * | 1987-09-08 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Method of preparing adhesive dressings containing a pharmaceutically active ingredient |
| NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US5147923A (en) * | 1987-10-05 | 1992-09-15 | Ciba-Geigy Corporation | Thermotropic biphilic hydrogels and hydroplastics |
| US5104954A (en) * | 1987-10-05 | 1992-04-14 | Ciba-Geigy Corporation | Thermostropic biphilic hydrogels and hydroplastics |
| US5057560A (en) * | 1987-10-05 | 1991-10-15 | Ciba-Geigy Corporation | Thermotropic copolymer hydrogels from N,N-dimethylacrylamide and methoxy-ethyl (meth) acrylate |
| US4948586A (en) * | 1987-11-02 | 1990-08-14 | Lim Technology Laboratories, Inc. | Microencapsulated insecticidal pathogens |
| JPH07116035B2 (en) * | 1987-12-08 | 1995-12-13 | 塩野義製薬株式会社 | Film-forming antifungal composition |
| JPH0749050B2 (en) * | 1988-01-18 | 1995-05-31 | 久光製薬株式会社 | Hydrous gel composition |
| US4883659A (en) * | 1988-08-24 | 1989-11-28 | Dento-Med Industries, Inc. | Skin treatment preparation |
| US5039516A (en) * | 1988-08-24 | 1991-08-13 | Dento-Med Industries, Inc. | Sunscreen preparation |
| US4927408A (en) * | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
| GB8909095D0 (en) * | 1989-04-21 | 1989-06-07 | Allied Colloids Ltd | Thickened aqueous compositions |
| US5009969A (en) * | 1989-05-26 | 1991-04-23 | Hi-Tek Polymers, Inc. | Dual action sunscreen composition |
| US5208031A (en) * | 1989-06-06 | 1993-05-04 | Kelly Patrick D | Sexual lubricants containing zinc as an anti-viral agent |
| US5100658A (en) * | 1989-08-07 | 1992-03-31 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
| FR2651126B1 (en) * | 1989-08-29 | 1991-12-06 | Oreal | COMBINATION OF DIHYDROXYACETONE AND INDOLIC DERIVATIVES FOR GIVING SKIN A SIMILAR COLOR TO NATURAL TANNING AND METHOD FOR IMPLEMENTING SAME. |
| GB2236760A (en) * | 1989-10-11 | 1991-04-17 | Inverness Corp | Shaving gel |
| FR2653334B1 (en) * | 1989-10-19 | 1991-12-20 | Erphar Ste Civile | COSMETIC TANNING PREPARATION. |
| FR2657607B1 (en) * | 1990-01-30 | 1992-04-30 | Durand Muriel | METHOD FOR PROTECTING DIHYDROXYACETONE, DIHYDROXYACETONE PROTECTED BY THIS PROCESS AND COSMETIC PRODUCT CONTAINING SUCH PROTECTED DIHYDROXYACETONE. |
| US5091443A (en) * | 1990-02-07 | 1992-02-25 | Becton, Dickinson And Company | Composition for gelling liquids |
| US5043359A (en) * | 1990-03-05 | 1991-08-27 | Dow Corning Corporation | Skin conditioning compositions containing glyceroxyfunctional silanes and siloxanes |
| US5110853A (en) * | 1990-08-27 | 1992-05-05 | Exxon Chemical Patents Inc. | Freeze-thaw stable polyacrylamide emulsions |
| US5169624A (en) * | 1991-02-23 | 1992-12-08 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Waterproof sunblock compositions |
| AU1775592A (en) * | 1991-04-03 | 1992-11-02 | Richardson-Vicks Inc. | Stabilized emulsion compositions for imparting an artificial tan to human skin |
| US5221530A (en) * | 1991-06-24 | 1993-06-22 | Helene Curtis, Inc. | Mild conditioning shampoo with a high foam level containing an anionic surfactant-cationic acrylate/acrylamide copolymer conditioning agent |
| CZ90494A3 (en) * | 1991-10-16 | 1994-07-13 | Richardson Vicks | Skin care preparation having the form of aqueous gel |
| BR9206632A (en) * | 1991-10-16 | 1995-04-25 | Richardson Vicks Inc | Improved skin penetration system for improved topical drug release |
| EG20380A (en) * | 1991-10-16 | 1999-02-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
| US5232688A (en) * | 1992-06-17 | 1993-08-03 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Self-tanner cosmetic compositions |
| US5302378A (en) * | 1992-06-17 | 1994-04-12 | Chesebrough-Pond's Usa Co. | Self-tanner cosmetic compositions |
| AU4673993A (en) * | 1992-07-28 | 1994-02-14 | Procter & Gamble Company, The | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
| US5618522A (en) * | 1995-01-20 | 1997-04-08 | The Procter & Gamble Company | Emulsion compositions |
-
1992
- 1992-10-13 BR BR9206632A patent/BR9206632A/en not_active Application Discontinuation
- 1992-10-13 AT AT92921755T patent/ATE162725T1/en not_active IP Right Cessation
- 1992-10-13 CA CA002120927A patent/CA2120927A1/en not_active Abandoned
- 1992-10-13 DE DE69224294T patent/DE69224294T2/en not_active Expired - Fee Related
- 1992-10-13 EP EP92921755A patent/EP0608320B1/en not_active Expired - Lifetime
- 1992-10-13 JP JP5507768A patent/JPH07500113A/en active Pending
- 1992-10-13 SK SK432-94A patent/SK43294A3/en unknown
- 1992-10-13 ES ES92921755T patent/ES2114569T3/en not_active Expired - Lifetime
- 1992-10-13 HU HU9401107A patent/HUT74560A/en unknown
- 1992-10-13 AU AU28064/92A patent/AU675211B2/en not_active Ceased
- 1992-10-13 CZ CS94859A patent/CZ85994A3/en unknown
- 1992-10-13 WO PCT/US1992/008741 patent/WO1993007902A1/en active IP Right Grant
- 1992-10-15 MA MA22967A patent/MA22680A1/en unknown
- 1992-10-15 PT PT100963A patent/PT100963A/en not_active Application Discontinuation
- 1992-10-16 CN CN92112390.6A patent/CN1072863A/en active Pending
-
1994
- 1994-04-15 FI FI941771A patent/FI941771A/en not_active Application Discontinuation
-
1995
- 1995-06-05 US US08/462,710 patent/US5773023A/en not_active Expired - Fee Related
- 1995-06-05 US US08/462,258 patent/US5756118A/en not_active Expired - Fee Related
- 1995-06-05 US US08/464,991 patent/US5780049A/en not_active Expired - Fee Related
- 1995-06-05 US US08/462,376 patent/US5756119A/en not_active Expired - Lifetime
- 1995-06-06 US US08/469,701 patent/US5776485A/en not_active Expired - Fee Related
-
1998
- 1998-03-27 US US09/049,367 patent/US5874095A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2114569T3 (en) | 1998-06-01 |
| DE69224294T2 (en) | 1998-08-20 |
| JPH07500113A (en) | 1995-01-05 |
| ATE162725T1 (en) | 1998-02-15 |
| CN1072863A (en) | 1993-06-09 |
| AU2806492A (en) | 1993-05-21 |
| MA22680A1 (en) | 1993-07-01 |
| HU9401107D0 (en) | 1994-08-29 |
| US5756118A (en) | 1998-05-26 |
| AU675211B2 (en) | 1997-01-30 |
| BR9206632A (en) | 1995-04-25 |
| EP0608320B1 (en) | 1998-01-28 |
| PT100963A (en) | 1993-10-29 |
| US5773023A (en) | 1998-06-30 |
| DE69224294D1 (en) | 1998-03-05 |
| CZ85994A3 (en) | 1994-12-15 |
| WO1993007902A1 (en) | 1993-04-29 |
| US5780049A (en) | 1998-07-14 |
| FI941771A0 (en) | 1994-04-15 |
| US5756119A (en) | 1998-05-26 |
| HUT74560A (en) | 1997-01-28 |
| SK43294A3 (en) | 1995-01-12 |
| FI941771A (en) | 1994-04-15 |
| US5874095A (en) | 1999-02-23 |
| US5776485A (en) | 1998-07-07 |
| EP0608320A1 (en) | 1994-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0608320B1 (en) | Enhanced skin penetration system for improved topical delivery of drugs | |
| EP0608322B1 (en) | Enhanced skin penetration system for improved topical delivery of drugs | |
| EP0652774B1 (en) | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether | |
| CN1114876A (en) | Use of a spin trap in a cosmetic or dermatological composition | |
| SK64599A3 (en) | Substantially homogenous liquid composition capable for percutaneous delivery of active agents and percutaneous delivery system | |
| WO1995022351A1 (en) | Composition for topical application | |
| JPH02204413A (en) | Antimycotic agent for external use | |
| Patel et al. | Emulgel: A novel approach for Topical drug delivery system | |
| EP0351897A2 (en) | Skin penetration system for salts of amine-functional drugs | |
| MX2011002568A (en) | Compositions for percutaneous administration. | |
| WO2012049453A2 (en) | Compositions for topical applications | |
| Mahoto et al. | Development and evaluation of nanoemulsion loaded gel of terbinafine hydrochloride for the treatment of fungal infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |